Xlife Sciences AG

Equities

XLS

CH0461929603

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
34.3 ^CHF	0.00%		+1.18%	-31.26%

Apr. 23	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
Feb. 29	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million.

October 17, 2023

Xlife Sciences AG (SWX:XLS) acquired 20% stake in 4D Lifetec AG for CHF 23.3 million on October 18, 2023.

Xlife Sciences AG (SWX:XLS) completed the acquisition of 20% stake in 4D Lifetec AG on October 18, 2023.

Latest news about Xlife Sciences AG

Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	Apr. 23	MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership	Feb. 05	MT
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection	Dec. 20	MT
Xlife Sciences to Sell Portfolio Company to 4D Lifetec	23-10-18	MT
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million.	23-10-17	CI
Xlife Sciences Loss Narrows in H1; Revenue Declines	23-09-21	MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Xlife Sciences AG Signs Memorandum of Understanding with the Regulator of the Healthcare Sector in the UAE, the Department of Health - Abu Dhabi	23-08-17	CI
Xlife Sciences AG Announces Bernhard Scholz Will Not Stand for Re-Election	23-05-26	CI
Xlife Sciences Posts Lower FY22 EPS; Revenue Increases	23-04-20	MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method	23-01-20	MT
Xlife Sciences' Portfolio Company To Research Therapy For Amyotrophic Lateral Sclerosis	23-01-16	MT
Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Lateral Sclerosis	23-01-15	CI
Xlife Sciences Portfolio Company Signs Exclusive License Agreement	22-12-01	MT
Xlife Sciences Unit Taps CureDiab For Morbid Obesity Research	22-11-28	MT
Xlife Sciences Begins Strategic Options Review To Accelerate Business Expansion	22-11-21	MT
Xlife Sciences' Portfolio Company Wins US Patent for Active Ingredient of Inflammatory Pain Drug	22-11-01	MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Xlife Sciences' H1 Loss Widen, Revenue Jumps in First Report Since SIX Swiss Transfer	22-09-28	MT
Xlife Sciences Adopts Annual ESG Reporting To Boost Transparency	22-09-21	MT
Xlife Sciences AG Announces Management Changes	22-04-29	CI
Xlife Sciences AG(SWX:XLS) added to Swiss Performance Index (Price Return)	22-02-14	CI
Xlife Sciences AG announced that it has received CHF 5.012469 million in funding	22-01-24	CI

Chart Xlife Sciences AG

Duration

Period

More charts

Company Profile

Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.

Sector

Biotechnology & Medical Research

Calendar

2024-06-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Xlife Sciences AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.3 CHF

Average target price

68 CHF

Spread / Average Target

+98.25%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XLIFE SCIENCES AG	-31.26%	214M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research